Publication:
HIV/HCV prevalence and the retention paradox in marginalized populations in Madrid (2019-2023): A large-scale cross-sectional study.

dc.contributor.authorValencia, Jorge
dc.contributor.authorRyan, Pablo
dc.contributor.authorCodina Márquez, Helena
dc.contributor.authorCuevas, Guillermo
dc.contributor.authorManzano, Samuel
dc.contributor.authorEstévez, Samuel
dc.contributor.authorMartinez, Isidoro
dc.contributor.authorSepulveda-Crespo, Daniel
dc.contributor.authorResino, Salvador
dc.contributor.funderGilead Sciences (Spain)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderAbbVie
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
dc.contributor.funderUnión Europea. Comisión Europea. NextGenerationEU
dc.date.accessioned2026-06-26T22:20:33Z
dc.date.available2026-06-26T22:20:33Z
dc.date.issued2026-06
dc.description.abstractObjectives: Marginalized urban populations experience a high burden of HIV and HCV. We assessed the prevalence and risk factors for both infections and characterized the care cascades in a cohort of vulnerable individuals in Madrid, Spain. Methods: We conducted a cross-sectional study (2019-2023) of 4582 individuals via mobile units in high-risk hotspots, offering integrated rapid HIV/HCV testing with point-of-care HCV-RNA confirmation. Multivariable logistic regression identified independent HIV risk factors. Results: HIV prevalence was 6.3% (95% CI: 5.6-7.0). Among people with HIV (PWH), 17.0% of known cases were not receiving antiretroviral therapy; PrEP uptake was zero among HIV-negative individuals. A history of injecting drug use was the primary HIV risk factor (adjusted odds ratio[aOR] 6.6; 95% CI: 4.6-9.5), followed by age >50 years, Spanish origin, and alcohol/benzodiazepine misuse (all P < 0.05). Active HCV prevalence was 5.5% (95% CI: 4.9-6.2); 15.7% in PWH vs 4.8% in people without HIV (P < 0.001). Among confirmed cases, HCV linkage (≥95.2%) and treatment (≥88.6%) were high; however, 16.8% of all antibody-positive individuals (23.2% among PWH) missed confirmatory RNA testing. Conclusions: HIV and HCV remain prevalent, characterized by discontinuities in retention rather than diagnosis. Integrated, low-threshold strategies combining harm reduction with social support are required to address this syndemic.
dc.description.peerreviewed
dc.description.sponsorshipThis work was supported by grants from Gilead Science (IN-ES-380-6205, IN-ES-987-5391, GLD19_0096 to PR, and GLD20_0144 to SR); Instituto de Salud Carlos III (ISCIII; grant numbers PI20CIII/00004 to SR, PI23CIII/00018 to DSC and IM); AbbVie; Madrid Positivo Association; and CIBER—Consorcio Centro de Investigación Biomédica en Red—(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and Unión Europea—NextGenerationEU (grant number CB21/13/00044 to SR). DSC is supported by a ‘Miguel Servet’ contract from ISCIII (CP23CIII/00004).
dc.format.page108582
dc.format.volume167
dc.identifier.citationValencia J, Ryan P, Codina H, Cuevas G, Manzano S, Estévez S, Martínez I, Sepúlveda-Crespo D, Resino S. HIV/HCV prevalence and the retention paradox in marginalized populations in Madrid (2019-2023): A large-scale cross-sectional study. Int J Infect Dis. 2026 Jun;167:108582. doi: 10.1016/j.ijid.2026.108582. Epub 2026 Mar 20. PMID: 41866060.
dc.identifier.doi10.1016/j.ijid.2026.108582
dc.identifier.journalInternational Journal of Infectious Diseases
dc.identifier.pubmedID41866060
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27569
dc.language.isoeng
dc.publisherElsevier
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Science//IN-ES-380-6205///
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Science//IN-ES-987-5391///
dc.relation.projectIDinfo:eu-repo/grantAgreement/Gilead Science//GLD19_0096///
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI20CIII%2F00004//Infecciones agudas%2Frecientes y reinfecciones por VHC en hombres que tienen sexo con hombres con y sin VIH/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI/PI23CIII%2F00018//Nanosistemas dentríticos aplicados al diagnóstico de infecciones virales/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII-CIBER-Ministerio de Ciencia e Innovación-Unión Europea–NextGenerationEU//CB21%2F13%2F00044/ES//
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/CP23CIII%2F00004/ES//
dc.relation.publisherversionhttps://doi.org/10.1016/j.ijid.2026.108582
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.repisalud.instituteIIS::IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid)
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHIV
dc.subjectHIV/HCV coinfection
dc.subjectLink to care
dc.subjectScreening
dc.subjectVulnerable populations
dc.subject.meshAdult
dc.subject.meshCoinfection
dc.subject.meshCross-Sectional Studies
dc.subject.meshFemale
dc.subject.meshHIV Infections
dc.subject.meshHepacivirus
dc.subject.meshHepatitis C
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrevalence
dc.subject.meshRisk Factors
dc.subject.meshSpain
dc.subject.meshSubstance Abuse, Intravenous
dc.subject.meshVulnerable Populations
dc.titleHIV/HCV prevalence and the retention paradox in marginalized populations in Madrid (2019-2023): A large-scale cross-sectional study.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication9031feac-3005-4a7b-bf28-4f0f582dc1dd
relation.isAuthorOfPublication91fafbb0-4d25-4be8-969e-5b9941af71ca
relation.isAuthorOfPublication3ef39da6-a7d1-43fc-8309-3429a6ea9918
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication.latestForDiscovery9031feac-3005-4a7b-bf28-4f0f582dc1dd
relation.isFunderOfPublicatione30731f7-32c2-43af-b658-fe28964bc958
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationffb8e2d3-a3e4-4345-ade9-736e37d36399
relation.isFunderOfPublication0b5a6d3a-4d4d-4346-9bcc-9359bbe13e72
relation.isFunderOfPublication54f29c6e-1163-4239-8d1d-a0f297ca06e6
relation.isFunderOfPublication.latestForDiscoverye30731f7-32c2-43af-b658-fe28964bc958
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
HIV_HCV_PrevalenceRetentionParadox_2026.pdf
Size:
1.36 MB
Format:
Adobe Portable Document Format